Ursodeoxycholic acid therapy in hepatobiliary disease

American Journal of Medicine

Volumn 108, Issue 6, 2000, Pages 481-486

  Kowdley, Kris V ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; AMINOTRANSFERASE; URSODEOXYCHOLIC ACID;

BILE FLOW; BILE SECRETION; CHOLESTASIS; CYSTIC FIBROSIS; DIARRHEA; DRUG ACTIVITY; DRUG EFFICACY; HUMAN; IMMUNOMODULATION; INTRAHEPATIC CHOLESTASIS; LIVER DISEASE; LIVER INJURY; LIVER PROTECTION; LIVER TRANSPLANTATION; LIVER VENOOCCLUSIVE DISEASE; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; REVIEW;

BILIARY TRACT DISEASES; BONE MARROW TRANSPLANTATION; CHOLAGOGUES AND CHOLERETICS; CHOLANGITIS, SCLEROSING; CHOLESTASIS; CHRONIC DISEASE; CYSTIC FIBROSIS; FEMALE; GRAFT REJECTION; GRAFT VS HOST DISEASE; HUMANS; LIVER CIRRHOSIS, BILIARY; LIVER DISEASES; LIVER TRANSPLANTATION; PARENTERAL NUTRITION, TOTAL; PREGNANCY; PREGNANCY COMPLICATIONS; URSODEOXYCHOLIC ACID;

EID: 0034655176     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(00)00318-1     Document Type: Review

References (49)

1. Vlahcevic ZR, Heuman DM, Hylemon PB. Physiology and pathophysiology of enterohepatic circulation of bile acids. In: Zakim D, Boyer TD, eds. Hepatology. A Textbook of Liver Disease, 3rd ed. Philadelphia: WB Saunders, 1998:377-415.
2. Heuman D.M. Quantitative estimation of the hydrophilic-hydrophobic balance of mixed bile salt solutions. J Lipid Res. 30:1989;719-730.
3. Beuers U., Boyer J.L., Paumgartner G. Ursodeoxycholic acid in cholestasis potential mechanisms of action and therapeutic applications . Hepatology. 28:1998;1449-1453.
4. Radominska A., Treat S., Little J. Bile acid metabolism and the pathophysiology of cholestasis. Semin Liver Dis. 13:1993;219-234.
5. Rubin R.A., Kowalski T.E., Khandelwal M., Malet P.F. Ursodiol for hepatobiliary disorders. Ann Intern Med. 121:1994;207-218.
6. Hillaire S., Boucher E., Calmus Y., et al. Effects of bile acids and cholestasis on major histocompatibility complex class I in human and rat hepatocytes. Gastroenterology. 107:1994;781-788.
7. Crosignani A., Setchell K.D., Invernizzi P., et al. Clinical pharmacokinetics of therapeutic bile acids. Clin Pharmacokinet. 30:1996;333-358.
8. Bachrach W.H., Hofmann A.F. Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis (Part I). Dig Dis Sci. 27:1982;737-761.
9. Paumgartner G. Ursodeoxycholic acid treatment of primary biliary cirrhosis: potential mechanisms of action. In: Lindor KD, Heathcote EJ, Poupon R, eds. Primary Biliary Cirrhosis: From Pathogenesis to Clinical Treatment. Dordrecht: Kluwer Academic Publishers, 1998:138-146.
10. Guldutuna S., Zimmer G., Imhof M., et al. Molecular aspects of membrane stabilization by ursodeoxycholate. Gastroenterology. 104:1993;1736-1744.
11. Poupon R.E., Chretien Y., Poupon R., Paumgartner G. Serum bile acids in primary biliary cirrhosis effect of ursodeoxycholic acid therapy . Hepatology. 17:1993;599-604.
12. Calmus Y., Gane P., Rouger P., Poupon R. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis effect of ursodeoxycholic acid . Hepatology. 11:1990;12-15.
13. Cirillo N.W., Zwas F.R. Ursodeoxycholic acid in the treatment of chronic liver disease. Am J Gastroenterol. 89:1994;1447-1452.
14. Bacon B.R., Farahvash M.J., Janney C.G., Neuschwander-Tetri B.A. Nonalcoholic steatohepatitis an expanded clinical entity . Gastroenterology. 107:1994;1103-1109.
15. Sheth S.G., Gordon F.D., Chopra S. Nonalcoholic steatohepatitis. Ann Intern Med. 126:1997;137-145.
16. Laurin J., Lindor K.D., Crippin J.S., et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis a pilot study . Hepatology. 23:1996;1464-1467.
17. Poupon R.E., Lindor K.D., Cauch-Dudek K., et al. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology. 113:1997;884-890.
18. Angulo P., Lindor K.D. Management of primary biliary cirrhosis and autoimmune cholangitis. Clin Liver Dis. 2:1998;333-351.
19. Emond M., Carithers R.L. Jr, Luketic V.A., et al. Does ursodeoxycholic acid improve survival in patients with primary biliary cirrhosis? Comparison of outcome in the U.S. multicenter trial to expected survival using the Mayo Clinic prognostic model. Hepatology. 24:1996;168A.
20. Goulis J., Leandro G., Burroughs A.K. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis a meta-analysis . Lancet. 354:1999;1053-1060.
21. Degott C., Zafrani E.S., Callard P., et al. Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression. Hepatology. 29:1999;1007-1012.
22. Pasha T., Heathcote J., Gabriel S., et al. Cost-effectiveness of ursodeoxycholic acid therapy in primary biliary cirrhosis. Hepatology. 29:1999;21-26.
23. Lindor K.D., Jorgensen R.A., Therneau T.M., et al. Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis. Mayo Clin Proc. 72:1997;1137-1140.
24. Poupon R.E., Balkau B., Eschwege E., Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. ursodeoxycholic acid-PBC Study Group. NEJM. 324:1991;1548-1554.
25. Lee Y.M., Kaplan M.M. Primary sclerosing cholangitis. NEJM. 332:1995;924-933.
26. Mitchell S.A., Chapman R.W.G. Management of primary sclerosing cholangitis. Clin Liver Dis. 2:1998;353-369.
27. Lindor K.D. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. NEJM. 336:1997;691-695.
28. Stiehl A., Rudolph G., Sauer P., et al. Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study. J Hepatol. 26:1997;560-566.
29. Saksena S., Tandon R.K. Ursodeoxycholic acid in the treatment of liver diseases. Postgrad Med J. 73:1997;75-80.
30. Reyes H. The enigma of intrahepatic cholestasis of pregnancy lessons from Chile . Hepatology. 2:1982;87-96.
31. Bacq Y., Sapey T., Brechot M.C., et al. Intrahepatic cholestasis of pregnancy a French prospective study . Hepatology. 26:1997;358-364.
32. Palma J., Reyes H., Ribalta J., et al. Effects of ursodeoxycholic acid in patients with intrahepatic cholestasis of pregnancy. Hepatology. 15:1992;1043-1047.
33. Almuna R., Liepins J., Lira F., et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy a randomized, double-blind study controlled with placebo . J Hepatol. 27:1997;1022-1028.
34. Fried R.H., Murakami C.S., Fisher L.D., et al. Ursodeoxycholic acid treatment of refractory chronic graft-versus-host disease of the liver. Ann Intern Med. 116:1992;624-629.
35. McGill J.M., Kwiatkowski A.P. Cholestatic liver diseases in adults. Am J Gastroenterol. 93:1998;684-691.
36. Colombo C., Battezzati P.M., Podda M., et al. Ursodeoxycholic acid for liver disease associated with cystic fibrosis a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic acid in Cystic Fibrosis . Hepatology. 23:1996;1484-1490.
37. Colombo C., Castellani M.R., Balistreri W.F., et al. Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease. Hepatology. 15:1992;677-684.
38. Shimokura G.H., McGill J.M., Schlenker T., Fitz J.G. Ursodeoxycholate increases cytosolic calcium concentration and activates Cl-currents in a biliary cell line. Gastroenterology. 109:1995;965-972.
39. Colombo C., Crosignani A., Assaisso M., et al. Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease a dose-response study . Hepatology. 16:1992;924-930.
40. Lindor K.D., Burnes J. Ursodeoxycholic acid for the treatment of home parenteral nutrition-associated cholestasis. A case report. Gastroenterology. 101:1991;250-253.
41. Beau P., Labat-Labourdette J., Ingrand P., Beauchant M. Is ursodeoxycholic acid an effective therapy for total parenteral nutrition-related liver disease? J Hepatol. 20:1994;240-244.
42. Friman S., Persson H., Schersten T., et al. Adjuvant treatment with ursodeoxycholic acid reduces acute rejection after liver transplantation. Transplant Proc. 24:1992;389-390.
43. Pageaux G.P., Blanc P., Perrigault P.F., et al. Failure of ursodeoxycholic acid to prevent acute cellular rejection after liver transplantation. J Hepatol. 23:1995;119-122.
44. Keiding S., Hockerstedt K., Bjoro K., et al. The Nordic multicenter double-blind randomized controlled trial of prophylactic ursodeoxycholic acid in liver transplant patients. Transplantation. 63:1997;1591-1594.
45. Barnes D., Talenti D., Cammell G., et al. A randomized clinical trial of ursodeoxycholic acid as adjuvant treatment to prevent liver transplant rejection. Hepatology. 26:1997;853-857.
46. Essell J.H., Schroeder M.T., Harman G.S., et al. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 128:1998;975-981.
47. Poupon R., Poupon R.E. Ursodeoxycholic acid therapy of chronic cholestatic conditions in adults and children. Pharmacol Ther. 66:1995;1-15.
48. Crosignani A., Budillon G., Cimino L., et al. Tauroursodeoxycholic acid for the treatment of HCV-related chronic hepatitis a multicenter placebo-controlled study . Hepatogastroenterology. 45:1998;1624-1629.
49. Abdelmalek M.F., Harrison M.E., Gross J.B. Jr, et al. Treatment of chronic hepatitis C with interferon with or without ursodeoxycholic acid a randomized prospective trial . J Clin Gastroenterol. 26:1998;130-134.